Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,

#1252 Radio-chemotherapy versus Surgery in Non-metastatic Ano-rectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues

Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Coriat R

Authors: Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R,

Keywords: Neuroendocrine carcinoma, ano-rectal tumor, surgery, radio-chemotherapy,

#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)

Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bernard V, Lombard-Bohas C, Goichot B, Rohmer V, Guimbaud R,

Keywords: pancreatic endocrine tumor, insulinoma, Everolimus, hypoglycemia,

#216 Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up

Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Guimbaud R, Valentin T, Duffas J, Carrere N, Otal P,

Keywords: neuroendocrine, tumors, well-differentiated, follow-up, multidisciplinary, lost care,